- Home
- GLRE vs AURA Comparison
GLRE vs AURA Comparison
Compare GLRE & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | AURA |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 419.5M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLRE | AURA |
|---|---|---|
| Price | $16.33 | $7.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 169.7K | ★ 756.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.96 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $4.73 |
| 52 Week High | $19.39 | $9.54 |
Technical Indicators
Market Signals| Indicator | GLRE | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 52.68 |
| Support Level | $13.77 | $5.87 |
| Resistance Level | $17.02 | $7.68 |
| Average True Range (ATR) | 0.50 | 0.37 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 2.17 | 38.16 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.